The DOI matches its Crossref record.
Atypical antipsychotic agents: A critical review
Abstract
The pharmacology, efficacy, and adverse effects of atypical antipsychotic agents when used to treat schizophrenia and other disorders are reviewed. Atypical antipsychotic agents were developed in response to problems with typical agents, including lack of efficacy in some patients, lack of improvement in negative symptoms, and troublesome adverse effects, especially extrapyramidal symptoms (EPSs) and tardive dyskinesia CTD). Atypical antipsychotics differ from typical psychotics in their "limbic-specific" dopamine type 2 (D2)-receptor binding and high ratio of serotonin type 2 (5-HT2)-receptor binding to D2 binding. In clinical trials in patients with non-treatment-resistant schizophrenia, risperidone and olanzapine were superior to placebo for positive and negative symptoms. Risperidone and olanzapine were superior to haloperidol on some measures. Quetiapine was better than placebo but was not better than typical antipsychotics. Head-to-head comparisons of atypical antipsychotics in non-treatment-resistant schizophrenia have been inconclusive. Clozapine remains the standard agent for treatment-resistant schizophrenia. Atypical agents are substantially more expensive than their typical antipsychotic counterparts. To fully determine the overall efficiency of these drugs, other potential benefits, such as improved quality of life, need to be factored in. Atypical antipsychotics are associated with a decreased capacity to cause EPSs, TD, neuroleptic malignant syndrome, and hyperprolactinemia. Clozapine carries a risk of agranulocytosis; the white blood cell count must be monitored. Atypical antipsychotics are increasingly being used for indications other than schizophrenia, such as the management of aggression, mania, and depression. Atypical antipsychotics are often considered first-line agents for treating schizophrenia and are promising treatment alternatives for other psychiatric and neurologic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
“, rigidity and akinesia, it led to the development of newer drugs, known as atypical neuroleptics, with little or no adverse effects on motor functions (77).”
BackgroundAripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
DeLeon, A., Patel, N. C., & Lynn Crismon, M. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 363
Dysregulation of Arousal and Amygdala-Prefrontal Systems in Paranoid Schizophrenia
Williams, L. M., Das, P., Harris, A. W. F., Liddell, B. B., Brammer, M. J., Olivieri, G., Skerrett, D., Phillips, M. L., David, A. S., Peduto, A., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.480 · Cited by 337
“The arousalinhibiting effect of atypical antipsychotic treatments was a key factor in initiating their development, and these agents are designed to more specifically target dopamine receptors in the limbic system (37).”
BackgroundCoyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318070-000000000-00000 · Cited by 330
Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles
Bellina, F., Cauteruccio, S., & Rossi, R. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.075 · Cited by 254
Sexual dysfunction and antipsychotic treatment
Cutler, A. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00113-0 · Cited by 176
“This theory is gaining acceptance as perhaps the primary mechanism as compared with the complementary hypothesis that limbic system selectivity and higher 5-HT2A to D2 binding ratios may account for the generally lower tendency to prolactin elevation and EPS in comparison with older agents (Worrel et al., 2000), altho…”
ResultThe psychopathology, medical management and dental implications of schizophrenia
FRIEDLANDER, A. H., & MARDER, S. R. (2002) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2002.0236 · Cited by 115
Metadata
- Authors
- Worrel, J. A., Marken, P. A., Beckman, S. E., & Ruehter, V. L.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-02-01
- Volume
- 57
- Issue
- 3
- Pages
- 238-255
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W1870664623
- Cited by
- 194
- References
- 0
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.